Document Detail


Validation of a Dutch translation of the fibromyalgia impact questionnaire.
MedLine Citation:
PMID:  16757485     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To validate a Dutch translation of the fibromyalgia impact questionnaire (FIQ).
MATERIALS AND METHODS: Data were taken from two randomized clinical trials on Spa treatment and venlafaxine in fibromyalgia (FM). Participants completed the Dutch FIQ and a set of validated questionnaires for general health (RAND-36), depression (Beck depression inventory, BDI), pain (McGill pain questionnaire, MPQ) and fatigue (checklist individual strength, CIS). Internal consistency within the FIQ item 'physical functioning' was studied using Cronbach's alpha. Test-retest reliability was studied with intra-class-correlation (ICC) in a subsample of 76 control subjects over a 3 month period without specific intervention. Construct validity was evaluated by correlating the FIQ to other questionnaires. Sensitivity to change was studied using standardized response means (SRM).
RESULTS: The study sample consisted of 213 women and 11 men (mean age 47 yrs, mean disease duration 11 yrs). Cronbach's alpha for the item 'physical functioning' was 0.91, indicating high internal consistency. Test-retest reliability was acceptable, with ICC ranging from 0.45 for 'morning tiredness' to 0.71 for 'physical function'. FIQ correlated significantly with the RAND-36, with Spearman's rho ranging from -0.60 to -0.70 for items measuring the same concept. Similar patterns of correlation were seen with MPQ, BDI and CIS. Sensitivity to change was sufficient, with SRM after Spa treatment ranging from 0.3 for 'work days missed' to 0.9 for 'days felt good'. Similar SRM were found in the venlafaxine trial for patients reporting general improvement.
CONCLUSION: The Dutch FIQ is a valid instrument for measuring health status in FM, showing sufficient reliability, construct validity and responsiveness.
Authors:
T R Zijlstra; E Taal; M A F J van de Laar; J J Rasker
Related Documents :
25045035 - Improving hand functional use in subjects with multiple sclerosis using a musical keybo...
20922485 - The rsm-scale: a pilot study on a new specific scale for self- and observer-rated quali...
2793085 - Measurement of spiritual well-being: a hospice caregiver sample.
2017915 - The translation and evaluation of an urdu version of the hospital anxiety and depressio...
17925875 - The environmental dependence of inbreeding depression in a wild bird population.
8947285 - Clozapine for the treatment of psychosis in parkinson's disease: a review.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Validation Studies     Date:  2006-06-06
Journal Detail:
Title:  Rheumatology (Oxford, England)     Volume:  46     ISSN:  1462-0324     ISO Abbreviation:  Rheumatology (Oxford)     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2006-12-13     Completed Date:  2007-03-30     Revised Date:  2014-07-29    
Medline Journal Info:
Nlm Unique ID:  100883501     Medline TA:  Rheumatology (Oxford)     Country:  England    
Other Details:
Languages:  eng     Pagination:  131-4     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Activities of Daily Living
Adult
Aged
Antidepressive Agents, Second-Generation / therapeutic use
Balneology
Cross-Cultural Comparison
Cyclohexanols / therapeutic use
Double-Blind Method
Female
Fibromyalgia / rehabilitation*,  therapy
Health Status Indicators*
Humans
Language
Male
Middle Aged
Netherlands
Psychiatric Status Rating Scales
Psychometrics
Questionnaires*
Reproducibility of Results
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antidepressive Agents, Second-Generation; 0/Cyclohexanols; GRZ5RCB1QG/venlafaxine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High resolution structures of p-aminobenzamidine- and benzamidine-VIIa/soluble tissue factor: unpred...
Next Document:  Emerging lessons from the drug effectiveness review project.